CGRP-monoclonal antibodies in Japan: insights from an online survey of physician members of the Japanese headache society
{{output}}
Background: Anti-calcitonin gene-related peptide monoclonal antibodies (CGRPmAbs) have greatly changed migraine treatment options. In Japan, although CGRPmAb guidelines (≥ 4 monthly migraine days (MMDs) and ≥ 1 previous prevent... ...
